Takeda traded at 3,759.00 this Friday July 1st, decreasing 59.00 or 1.55 percent since the previous trading session. Looking back, over the last four weeks, Takeda lost 4.16 percent. Over the last 12 months, its price rose by 0.16 percent. Looking ahead, we forecast Takeda to be priced at 3,583.19 by the end of this quarter and at 3,236.01 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
3,759.00
Daily Change
-1.55%
Yearly
0.16%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
M3 Inc 3,786.00 -112.00 -2.87% -52.88%
Kyowa Hakko Kirin 3,035.00 -15.00 -0.49% -23.26%
Takeda 3,759.00 -59.00 -1.55% 0.16%
Astellas Pharma 2,058.50 -56.50 -2.67% 6.99%
Sumitomo Dainippon 1,080.00 -11.00 -1.01% -52.67%
Shionogi 6,734.00 -121.00 -1.77% 16.87%
Chugai Pharma 3,476.00 6.00 0.17% -21.00%
Eisai 5,691.00 -34.00 -0.59% -47.57%
Terumo 4,013.00 -75.00 -1.83% -9.64%
Daiichi Sankyo 3,376.00 -61.00 -1.77% 41.73%
Otsuka Holdings 4,769.00 -49.00 -1.02% 4.35%

Indexes Price Day Year
JP225 25936 -457.42 -1.73% -9.89%

Takeda
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.